-
Bounding causal effects with an unknown mixture of informative and non-informative censoring
Authors:
Max Rubinstein,
Denis Agniel,
Larry Han,
Marcela Horvitz-Lennon,
Sharon-Lise Normand
Abstract:
In experimental and observational data settings, researchers often have limited knowledge of the reasons for censored or missing outcomes. To address this uncertainty, we propose bounds on causal effects for censored outcomes, accommodating the scenario where censoring is an unobserved mixture of informative and non-informative components. Within this mixed censoring framework, we explore several…
▽ More
In experimental and observational data settings, researchers often have limited knowledge of the reasons for censored or missing outcomes. To address this uncertainty, we propose bounds on causal effects for censored outcomes, accommodating the scenario where censoring is an unobserved mixture of informative and non-informative components. Within this mixed censoring framework, we explore several assumptions to derive bounds on causal effects, including bounds expressed as a function of user-specified sensitivity parameters. We develop influence-function based estimators of these bounds to enable flexible, non-parametric, and machine learning based estimation, achieving root-$n$ convergence rates and asymptotic normality under relatively mild conditions. We further consider the identification and estimation of bounds for other causal quantities that remain meaningful when informative censoring reflects a competing risk, such as death. We conduct extensive simulation studies and illustrate our methodology with a study on the causal effect of antipsychotic drugs on diabetes risk using a health insurance dataset.
△ Less
Submitted 3 February, 2025; v1 submitted 25 November, 2024;
originally announced November 2024.
-
Estimating Racial and Ethnic Healthcare Quality Disparities Using Exploratory Item Response Theory and Latent Class Item Response Theory Models
Authors:
Sharon-Lise Normand,
Katya Zelevinsky,
Marcela Horvitz-Lennon
Abstract:
Healthcare quality metrics refer to a variety of measures used to characterize what should have been done or not done for a patient or the health consequences of what was or was not done. When estimating healthcare quality, many metrics are measured and combined to provide an overall estimate either at the patient level or at higher levels, such as the provider organization or insurer. Racial and…
▽ More
Healthcare quality metrics refer to a variety of measures used to characterize what should have been done or not done for a patient or the health consequences of what was or was not done. When estimating healthcare quality, many metrics are measured and combined to provide an overall estimate either at the patient level or at higher levels, such as the provider organization or insurer. Racial and ethnic disparities are defined as the mean difference in quality be tween minorities and Whites not justified by underlying health conditions or patient preferences. Several statistical features of healthcare quality data have been ignored: quality is a theoretical construct not directly observable; quality metrics are measured on different scales or, if measured on the same scale, have different baseline rates; the construct may be multidimensional; and metrics are correlated within-individuals. Balancing health differences across race and ethnicity groups is challenging due to confounding. We provide an approach addressing these features, utilizing exploratory multidimensional item response theory (IRT) models and latent class IRT models to estimate quality, and optimization-based matching to adjust for confounding among the race and ethnicity groups. Quality metrics measured on 93,000 adults with schizophrenia residing in five U.S. states illustrate approaches.
△ Less
Submitted 12 February, 2025; v1 submitted 4 May, 2023;
originally announced May 2023.
-
Targeted learning in observational studies with multi-valued treatments: An evaluation of antipsychotic drug treatment safety
Authors:
Jason Poulos,
Marcela Horvitz-Lennon,
Katya Zelevinsky,
Tudor Cristea-Platon,
Thomas Huijskens,
Pooja Tyagi,
Jiaju Yan,
Jordi Diaz,
Sharon-Lise Normand
Abstract:
We investigate estimation of causal effects of multiple competing (multi-valued) treatments in the absence of randomization. Our work is motivated by an intention-to-treat study of the relative cardiometabolic risk of assignment to one of six commonly prescribed antipsychotic drugs in a cohort of nearly 39,000 adults with serious mental illnesses. Doubly-robust estimators, such as targeted minimum…
▽ More
We investigate estimation of causal effects of multiple competing (multi-valued) treatments in the absence of randomization. Our work is motivated by an intention-to-treat study of the relative cardiometabolic risk of assignment to one of six commonly prescribed antipsychotic drugs in a cohort of nearly 39,000 adults with serious mental illnesses. Doubly-robust estimators, such as targeted minimum loss-based estimation (TMLE), require correct specification of either the treatment model or outcome model to ensure consistent estimation; however, common TMLE implementations estimate treatment probabilities using multiple binomial regressions rather than multinomial regression. We implement a TMLE estimator that uses multinomial treatment assignment and ensemble machine learning to estimate average treatment effects. Our multinomial implementation improves coverage, but does not necessarily reduce bias, relative to the binomial implementation in simulation experiments with varying treatment propensity overlap and event rates. Evaluating the causal effects of the antipsychotics on three-year diabetes risk or death, we find a safety benefit of moving from a second-generation drug considered among the safest of the second-generation drugs to an infrequently prescribed first-generation drug known for having low cardiometabolic risk.
△ Less
Submitted 28 November, 2023; v1 submitted 30 June, 2022;
originally announced June 2022.
-
Bayesian Meta-Analysis of Multiple Continuous Treatments: An Application to Antipsychotic Drugs
Authors:
Jacob Spertus,
Marcela Horvitz-Lennon,
Sharon-Lise Normand
Abstract:
Modeling dose-response relationships of drugs is essential to understanding their effect on patient outcomes under realistic circumstances. While intention-to-treat analyses of clinical trials provide the effect of assignment to a particular drug and dose, they do not capture observed exposure after factoring in non-adherence and dropout. We develop Bayesian methods to flexibly model dose-response…
▽ More
Modeling dose-response relationships of drugs is essential to understanding their effect on patient outcomes under realistic circumstances. While intention-to-treat analyses of clinical trials provide the effect of assignment to a particular drug and dose, they do not capture observed exposure after factoring in non-adherence and dropout. We develop Bayesian methods to flexibly model dose-response relationships of binary outcomes with continuous treatment, allowing for treatment effect heterogeneity and a non-linear response surface. We use a hierarchical framework for meta-analysis with the explicit goal of combining information from multiple trials while accounting for heterogeneity. In an application, we examine the risk of excessive weight gain for patients with schizophrenia treated with the second generation antipsychotics paliperidone, risperidone, or olanzapine in 14 clinical trials. Averaging over the sample population, we found that olanzapine contributed to a 15.6% (95% CrI: 6.7, 27.1) excess risk of weight gain at a 500mg cumulative dose. Paliperidone conferred a 3.2% (95% CrI: 1.5, 5.2) and risperidone a 14.9% (95% CrI: 0.0, 38.7) excess risk at 500mg olanzapine equivalent cumulative doses. Blacks had an additional 6.8% (95% CrI: 1.0, 12.4) risk of weight gain over non-blacks at 1000mg olanzapine equivalent cumulative doses of paliperidone.
△ Less
Submitted 14 February, 2018;
originally announced February 2018.
